<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 28, 1998
MEDIRISK, INC.
(Exact name of registrant
as specified in its charter)
Delaware 000-22005 58-2256400
-------------------------------------------------------------------------
(State or other (Commission (I.R.S. Employer
jurisdiction of File Number) Identification No.)
incorporation)
<TABLE>
<CAPTION>
Two Piedmont Center, Suite 400, 3565 Piedmont Road, N.E., Atlanta, Georgia 30305
- --------------------------------------------------------------------------------------------------
<S> <C>
(Address of principal executive officers) (Zip Code)
</TABLE>
Registrant's telephone number, including area code: (404) 364-6700
N/A
-------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE> 2
ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS.
On May 28, 1998, Medirisk, Inc. (the "Company") acquired by merger all
of the capital stock of Successful Solutions, Inc., a Georgia corporation
("Successful Solutions"), for 190,000 shares of the Company's $0.001 par value
per share common stock (the "Medirisk Common Stock") and approximately $2.9
million in cash (the "Acquisition"). The Acquisition was made pursuant to an
Acquisition Agreement and Plan of Merger dated as of May 28, 1998 by and among
the Company, a newly formed merger subsidiary of the Company, Successful
Solutions and the shareholders of Successful Solutions (the "Acquisition
Agreement"). The Acquisition Agreement provides for payment of additional
contingent consideration upon the achievement of certain performance objectives.
Such additional contingent consideration will be paid in combinations of cash
and Medirisk Common Stock.
To finance the cash portion of the purchase price, the Company used
borrowings under its existing revolving credit facility with NationsBank. As a
result of these borrowings, at May 28, 1998 the Company had $9.8 million in
borrowings outstanding under its credit facility.
The Company and Successful Solutions also entered into Employment
Agreements with a senior executive of Successful Solutions. The purchase price
and other terms of the Acquisition were determined as a result of arms' length
negotiations between unrelated parties. At the closing date, there was no
material relationship between the Company and Successful Solutions or any of the
Successful Solutions shareholders, or any of their respective affiliates,
officers, directors or associates.
Successful Solutions, based in Vidalia, Georgia, provides
decision-support tools, consulting services and training materials to hospitals
and physician group practices to assist them in improving patient outcomes,
achieving the efficient delivery of care and in establishing billing and coding
practices that comply with industry requirements. Successful Solutions collects
clinical and billing data from its customers and profiles the relative
performance of individual physicians using its analytical tools and statistical
algorithms. Successful Solutions implements on-site education through physician
consultants and medical record specialists to influence physician behavior and
promote the effective and efficient delivery of health care. Successful
Solutions' analytical tools and services for bill coding and medical record
documentation help its customers achieve optimal and appropriate reimbursement
for services delivered, while improving the quality of data for future
comparative analysis.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(A) FINANCIAL STATEMENTS OF BUSINESS ACQUIRED.
It is impractical to provide financial statements for Successful
Solutions, to the extent required, at the date of the filing of this Form 8-K.
The financial statements, if required, will be provided as soon as practicable
but not later than 60 days after the date on which this Form 8-K is filed.
(B) PRO FORMA FINANCIAL INFORMATION.
It is impractical to file the pro forma financial information for
Successful Solutions, to the extent required, at the date of the filing of this
Form 8-K. The pro forma financial information, if required, will be provided as
soon as practicable, but not later than 60 days after the date on which this
Form 8-K is filed.
(C) EXHIBITS.
2.7 Acquisition Agreement and Plan of Merger, dated as of May 28,
1998, by and among Medirisk, Inc., Successful Solutions, Inc.,
a Delaware corporation, Successful Solutions, Inc., a Georgia
corporation, and Ronnie R. Smith, M.D., individually and as
attorney-in-fact. In accordance with Item 601(b)(2) of
Regulation S-K, the Exhibits and Schedules to the Stock
Purchase
-2-
<PAGE> 3
Agreement have not been filed as exhibits to this Form 8-K.
The Registrant agrees to furnish supplementally a copy of the
omitted Exhibits and Schedules upon request.
99.1 Press Release issued May 28, 1998, regarding the acquisition
of Successful Solutions.
-3-
<PAGE> 4
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
MEDIRISK, INC.
By: /s/ Thomas C. Kuhn III
-------------------------------------------
Thomas C. Kuhn III
Vice President and Chief Accounting Officer
Dated: May 29, 1998
-4-
<PAGE> 5
EXHIBIT INDEX
<TABLE>
<CAPTION>
PAGE
----
<S> <C> <C>
2.7 Acquisition Agreement and Plan of Merger, dated May 28, 1998,
by and among Medirisk, Inc., Successful Solutions, Inc., a
Delaware corporation, Successful Solutions, Inc., a Georgia
corporation, and Ronnie R. Smith, M.D., individually and as
attorney-in-fact.
99.1 Press Release issued May 28, 1998, regarding the acquisition
of Successful Solutions.
</TABLE>
<PAGE> 1
EXHIBIT 2.7
ACQUISITION AGREEMENT AND PLAN OF MERGER
THIS ACQUISITION AGREEMENT AND PLAN OF MERGER (this "Agreement"), is
made this 28th day of May 1998, by and among MEDIRISK, INC., a Delaware
corporation ("Medirisk"), SUCCESSFUL SOLUTIONS, INC., a Delaware corporation and
wholly-owned subsidiary of Medirisk ("Merger Sub"), SUCCESSFUL SOLUTIONS, INC.,
a Georgia corporation (the "Company"), and the shareholders of the Company as
set forth on Schedule 2.2A hereof (the shareholders of the Company being
collectively referred to as the "Shareholders," and each individually as a
"Shareholder").
W I T N E S S E T H:
WHEREAS, the parties desire to enter into this Agreement pursuant to
which the Company will merge with and into Merger Sub, such that Medirisk will
indirectly acquire all of the outstanding capital stock of the Company (the
"Company Stock") from the Shareholders, upon the terms and subject to the
conditions set forth herein (the "Merger"); and
WHEREAS, the respective Boards of Directors of Medirisk, Merger Sub and
the Company have approved the transactions contemplated by this Agreement;
NOW, THEREFORE, in consideration of the premises and the mutual
promises, representations, warranties and covenants hereinafter set forth, the
parties hereto agree as follows:
ARTICLE I
MERGER OF THE COMPANY AND MERGER SUB
1.1 MERGER. Subject to the terms and conditions of this Agreement, at
the Merger Effective Time (as defined in Section 1.2), the Company shall be
merged with and into Merger Sub in accordance with the provisions of the
business corporation act under the Georgia Business Corporation Code (the "GBCC
") and Delaware General Corporation Law (the "DGCL"). Merger Sub shall be the
surviving corporation resulting from the Merger and shall thereafter conduct the
business and operations of the Company as a wholly-owned subsidiary of Medirisk.
The Merger shall be consummated pursuant to the terms of this Agreement.
1.2 FILING OF MERGER CERTIFICATES. Subject to the provisions of this
Agreement, the parties shall file Articles or a Certificate of Merger, as
appropriate (the "Georgia Merger Certificate") executed in accordance with the
relevant provisions of the GBCC and a Certificate of Merger executed in
accordance with the relevant provisions of the DGCL (the "Delaware Merger
Certificate") and shall make all other filings or recordings required under each
such act as
<PAGE> 2
soon as practicable on or after the Closing Date. The Merger shall become
effective on the date and at the time the Delaware Merger Certificate becomes
effective with the Secretary of State of Delaware (the "Merger Effective Time").
1.3 ARTICLES AND BYLAWS. The Articles of Incorporation and Bylaws of
Merger Sub in effect immediately prior to the Merger Effective Time shall be the
Articles of Incorporation and Bylaws of the surviving corporation until
otherwise amended or repealed; the directors of Merger Sub immediately prior to
the Merger Effective Time shall serve as the directors of the surviving
corporation from and after the Merger Effective Time; and the officers of Merger
Sub in office immediately prior to the Merger Effective Time shall serve as the
officers of the surviving corporation from and after the Merger Effective Time.
1.4 [INTENTIONALLY OMITTED.]
1.5 MERGER CONSIDERATION. Subject to the provisions of this Section,
and in consideration for the transactions contemplated hereby, at the Merger
Effective Time, by virtue of the Merger and without any action on the part of
the parties hereto or the shareholders of any of the parties hereto, the shares
of the constituent corporations of the Merger shall be converted as follows:
(a) Each share of common stock of Merger Sub issued and
outstanding at the Merger Effective Time shall remain issued and outstanding
after the Merger Effective Time.
(b) The shares of Company Stock issued and outstanding at the
Merger Effective Time shall cease to be outstanding and shall in the aggregate
be converted into and exchanged for the right to receive:
(i) Initial Merger Consideration (as hereinafter
defined); and
(ii) Additional Consideration (as hereinafter defined).
(c) Certain Definitions:
(i) "Additional Consideration" means the additional
consideration payable to the Shareholders for the Company Stock as calculated
and upon the terms set forth in SCHEDULE 1.5(B)(II) attached hereto.
(ii) "Cash Initial Consideration" means the cash
consideration payable to the Shareholders for the Company Stock pursuant to
SCHEDULE 1.5(B)(I).
(iii) "Closing Market Value" means the average closing
price of Medirisk Common Stock on the Nasdaq National Market over the twenty
(20) trading days immediately preceding the Closing Date (as defined in Section
7.1 hereof).
-2-
<PAGE> 3
(iv) "Initial Merger Consideration" means the amount of
$7,300,000.00 to be paid to the Shareholders for the Company Stock, payable in
cash and/or unregistered shares of common stock of Medirisk ("Medirisk Common
Stock") upon the terms set forth in SCHEDULE 1.5(B)(I) attached hereto.
(v) "Merger Consideration" means the total consideration
payable to the Shareholders for the Company Stock pursuant to Section 1.5(b).
(vi) "Stock Initial Consideration" means the Medirisk
Common Stock to be issued to the Shareholders to the Shareholders for the
Company Stock pursuant to SCHEDULE 1.5(B)(I).
(d) Notwithstanding the foregoing, each holder of shares of
Company Stock who would otherwise be entitled to receive a fraction of a share
of Medirisk Common Stock shall receive, in lieu thereof, cash (without interest)
in an amount equal to such fractional part of a share of Medirisk Common Stock
multiplied by the Closing Market Value.
1.6 TAX EFFECT. Medirisk, the Company and the Shareholders intend
the Merger be a reorganization within the meaning of Section 368 of the Internal
Revenue Code of 1986, as amended (a "Reorganization" and the "Code,"
respectively). In connection with that intention, the persons indicated below
make the following representations and warranties.
(a) The Company represents and warrants to Medirisk and Merger
Sub that, except as otherwise disclosed in the Schedules to this Agreement, the
Company has not taken or agreed to take any action, nor does the Company have
any Knowledge of any fact or circumstance that is reasonably likely to prevent
the Merger from qualifying as a Reorganization. The Company agrees to use
reasonable efforts to cause the Merger to qualify, and not to take action which
would cause the Merger not to qualify, as a Reorganization. As used in this
Agreement, when any statement is made to the "Knowledge" of a person, it means
to the actual knowledge of such person without any duty on the part of such
person to independently investigate or confirm the accuracy of such statement.
(b) Medirisk and the Merger Sub represent and warrant to the
Company and the Shareholders of the Company that, except as otherwise disclosed
in the Schedules to this Agreement, neither Medirisk nor the Merger Sub has
taken or agreed to take any action, nor do either of Medirisk or the Merger Sub
have any Knowledge of any fact or circumstance that is reasonably likely, to
prevent the Merger from qualifying as a Reorganization. Medirisk and the Merger
Sub agree to use reasonable efforts to cause the Merger to qualify, and not to
take action which would cause the Merger not to qualify, as a Reorganization;
provided, however, that nothing in this Section 1.6 shall affect the
Shareholders' right to receive the Additional Consideration as described in this
Agreement.
(c) Medirisk, the Merger Sub, the Company and the Shareholders
understand that (i) neither Medirisk, the Merger Sub, the Company, nor any of
the Shareholders makes any representation or warranty that the Merger will be
regarded as a Reorganization, (ii) the Closing
-3-
<PAGE> 4
is not subject to a condition that an Internal Revenue Service ruling or tax
opinion be obtained as to the federal income tax consequences of this Agreement
or the Merger, and (iii) Medirisk, the Merger Sub, the Company and the
Shareholders will rely solely upon their respective advisors for advice
concerning the tax consequences of the Merger.
(d) The Company represents that, in the Merger, Merger Sub
will acquire assets representing at least ninety percent (90%) of the fair
market value of the net assets and at least seventy percent (70%) of the fair
market value of the gross assets held by the Company immediately prior to the
Merger. For this purpose, all redemptions and distributions (except for regular,
normal dividends) made by the Company immediately preceding the Merger and all
amounts paid out of the assets of the Company as Reorganization expenses will be
considered as assets held by the Company immediately prior to the Merger. In
addition, assets disposed of in contemplation of the Merger will be considered
as assets held by the Company immediately prior to the Merger.
(e) The Company warrants that the liabilities of the Company
to be assumed by Merger Sub or Medirisk in the Merger (and the liabilities to
which the assets to be transferred are subject) were incurred or will be
incurred by the Company in the ordinary course of its business.
(f) Medirisk and Merger Sub warrant that there is not now, nor
will there be at the time of the Merger Effective Time, any intercorporate
indebtedness existing between the Company and Medirisk or between Company and
Merger Sub that was issued, acquired, or will be settled at a discount.
(g) The Company represents that the Shareholders will pay, or
reimburse the Company as provided in Section 10.5 below, direct costs and
expenses incurred by the Shareholders, or by the Company on their behalf, in
connection with the Merger. Medirisk, Merger Sub, and the Company will pay their
respective expenses, if any, incurred in connection with the Merger.
(h) Each of Medirisk, Merger Sub and the Company represents
that it is not an Investment Company. As used in this Section 1.6(h),
"Investment Company" means a regulated investment company, a real estate
investment trust, or a corporation 50 percent or more of the value of whose
total assets are stock and securities and 80 percent or more of the value of
whose total assets are assets held for investment. In making the 50-percent and
80-percent determinations under the preceding sentence, stock and securities in
any subsidiary corporation shall be disregarded and the parent corporation shall
be deemed to own its ratable share of the subsidiary's assets, and a corporation
shall be considered a subsidiary if the parent owns 50 percent or more of the
combined voting power of all classes of stock entitled to vote, or 50 percent or
more of the total value of shares of all classes of stock outstanding.
(i) The Company and the Shareholders represent that the
Company is not under the jurisdiction of a court in a case under Title 11 of the
United States Code, a receivership, foreclosure, or similar proceeding in a
federal or state court.
-4-
<PAGE> 5
(j) The Company and the Shareholders represent that the fair
market value of the assets to be transferred from the Company to Merger Sub as a
result of the Merger will equal or exceed the sum of the liabilities of the
Company to be assumed by Merger Sub or Medirisk (plus the amount of liabilities
to which the assets to be transferred are subject).
(k) Medirisk represents the payment of cash to the
Shareholders in lieu of fractional shares of Medirisk Stock will not be a
separately bargained for consideration, but will be undertaken solely for the
purpose of avoiding the expense and inconvenience of issuing and transferring
fractional shares, and the total cash consideration that will be paid to the
Company's Shareholders in lieu of fractional shares of Medirisk Stock will
represent less than one (1%) percent of the total consideration issued in the
Merger.
(l) The Shareholders represent that none of the compensation
to be received by them for services as employees of the Company represents
separate consideration for, or is allocable to, any of their shares of Company
Stock. Medirisk represents that any compensation to be paid to a
Shareholder-employee who continues as an employee of Medirisk or Merger Sub
subsequent to the Merger will be for services rendered and will be not greater
in amounts than amounts that would be paid to third parties bargaining at arms
length for similar services.
(m) The Company represents that it has no plan or intention to
make prior to the Merger Effective Time, and except as set forth in SCHEDULE
1.6(M), it has not made, any distributions other than regular, normal dividends
to Shareholders in the three (3) year period prior to the Merger.
(n) The Company represents that except as set forth in
SCHEDULE 1.6(N), it has not reacquired or redeemed any of its stock within the
last three years.
(o) The Company represents that at all times during the
five-year period ending on the Merger Effective Time, the fair market value of
all of the Company's United States real property interests was and will have
been less than fifty (50%) percent of the total fair market value of (A) its
United States real property interests, (B) its interests in real property
located outside the United States, and (C) its other assets used or held for use
in a trade or business. For purposes of the preceding sentence, (X) United
States real property interests include all interests (other than an interest
solely as a creditor) in real property and associated personal property (such as
movable walls and furnishings) located in the United States or the Virgin
Islands and interests in any corporation (other than a controlled corporation)
owning any United States real property interest, (Y) the Company is treated as
owning its proportionate share (based on the relative fair market value of its
ownership interest to all ownership interests) of the assets owned by any
controlled corporation or any partnership, trust, or estate in which the Company
is a partner or beneficiary, and (Z) any such entity in turn is treated as
owning its proportionate share of the assets owned by any controlled corporation
or any partnership, trust, or estate in which the entity is a partner or
beneficiary. As used in this paragraph, "controlled corporation" means any
corporation at least fifty percent (50%) of the fair market value of the stock
of which is owned by the Company, in the case of a first-tier subsidiary of the
Company, or by a controlled corporation, in the case of a lower-tier subsidiary.
-5-
<PAGE> 6
(p) The Company represents that the Company is not a party to,
and holds no assets subject to, a "safe harbor lease" under former Section
168(f)(8) of the Code and the Regulations thereunder.
(q) The Agreement together with the other agreements to be
executed and delivered in connection with the Closing of the transactions
contemplated herein represent the entire understanding of Company, Medirisk, and
Merger Sub with respect to the Merger.
(r) Medirisk and Merger Sub represent that none of (i)
Medirisk, (ii) any member of Medirisk's affiliated group as defined in Section
1504 of the Code without regard to Section 1504(b) of the Code, (iii) any
corporation in which at least fifty percent (50%) of the total combined voting
power of all classes of stock entitled to vote or at least fifty percent (50%)
of the value of all classes of stock is owned directly or indirectly by Medirisk
or (iv) any entity that is treated as a partnership for federal income tax
purposes and has as an owner a corporation described in (I), (ii), or (iii) of
this paragraph has the intent at the time of the Closing to acquire or redeem
(directly or indirectly) any Medirisk shares issued in connection with the
transactions described herein.
(s) Medirisk and Merger Sub represent and warrant to the
Company that following the Merger, Merger Sub will not issue additional shares
of Merger Sub stock that would result in Medirisk losing control of Merger Sub
within the meaning of Section 368(c) of the Code.
(t) Medirisk represents and warrants to the Company that
Medirisk has no plan or intention to reacquire any of Medirisk's stock issued in
the Merger.
(u) Medirisk represents and warrants to the Company that
Medirisk has no plan or intention to: liquidate Merger Sub, merge Merger Sub
with and into another corporation; sell or otherwise dispose of the stock of
Merger Sub; or cause Merger Sub to sell or otherwise dispose of any of the
assets of the Company acquired in the Merger, except for dispositions made in
the ordinary course of business or transfers described in Section 368(a)(2)(C)
of the Code.
(v) Medirisk and Merger Sub represent and warrant to the
Company that, following the Merger, Merger Sub will continue the historic
business of the Company or use a significant portion of the Company's business
assets in a business.
(w) Medirisk represents and warrants to the Company that,
prior to the Merger, Medirisk will be in control of Merger Sub within the
meaning of Section 368(c) of the Code.
[Document Continued On Next Page]
-6-
<PAGE> 7
ARTICLE II
REPRESENTATIONS AND WARRANTIES OF THE COMPANY
The Company represents and warrants to Medirisk as follows:
2.1 ORGANIZATION AND STANDING. The Company is a corporation duly
organized, validly existing and in good standing under the laws of the State of
Georgia with the full power and authority to carry on its business in the places
and as it is now being conducted and to own and lease the properties and assets
it now owns or leases. Except as set forth on SCHEDULE 2.1, the Company is duly
qualified to transact business and in good standing in the other states listed
on SCHEDULE 2.1, which are the only additional jurisdictions in which operations
of the Company's business or the assets of the Company require such
qualification
2.2 AUTHORITY AND STATUS. The Company has the corporate power and
authority to execute and deliver this Agreement, to perform its obligations
hereunder and to consummate the transactions contemplated by this Agreement
without the necessity of any act or consent not previously obtained of any other
person whomsoever. This Agreement and each and every agreement, document and
instrument to be executed, delivered and performed in connection with this
Agreement (the "Transaction Documents") by the Company constitutes or will, when
executed and delivered, constitute the valid and legally binding obligations of
the Company, enforceable against the Company in accordance with their respective
terms, except as enforceability may be limited by applicable equitable
principles (whether applied with action at law or in equity) or by bankruptcy,
insolvency, reorganization, moratorium or similar laws from time to time in
effect affecting the enforcement of creditors' rights generally.
2.3 CAPITALIZATION; OWNERSHIP OF COMPANY STOCK. The authorized capital
stock of the Company consists of 1,000,000 shares of common stock, par value
$1.00 per share. The Company has 625 shares of common stock which are issued and
outstanding. All of the issued and outstanding shares or Company Stock are duly
and validly issued and outstanding, are fully paid and nonassessable, and were
issued pursuant to a valid exemption from registration under the Securities Act
of 1933, as amended, and all applicable state securities laws. Except as set
forth on SCHEDULE 2.3, there are no outstanding warrants, options, rights, calls
or other commitments of any nature relating to the common stock or any other
capital stock of the Company, and there are no outstanding securities of the
Company convertible into or exchangeable for shares of common stock or any other
capital stock of the Company.
2.4 SUBSIDIARIES, INVESTMENTS AND PREDECESSORS. Except as set forth on
SCHEDULE 2.4, the Company has not owned and does not currently own, directly or
indirectly, of record, beneficially or equitably any capital stock or other
equity, ownership or proprietary interest in any corporation, partnership,
limited liability company, association, trust, joint venture or other entity.
Set forth on SCHEDULE 2.4 is a listing for the last five years of all
predecessor companies of the Company, including the names of any and all
entities from which the Company previously acquired material assets, and any
other entity of which the Company has been a subsidiary or division. Except as
listed on SCHEDULE 2.4, the Company has not sold or disposed
-7-
<PAGE> 8
of, by way of asset sale, stock sale, spin-off, split-up or otherwise, any
material assets or business of the Company.
2.5 LIABILITIES AND OBLIGATIONS OF THE COMPANY.
(a) Attached as SCHEDULE 2.5 are true, correct and complete
copies of the Company's unaudited balance sheets as of 31 December 1995 and 1996
and audited balance sheet as of 31 December 1997 and the related statements of
operations and cash flows for the fiscal years ending on 31 December 1995, 1996
and 1997 (the "Financial Statements"). Also attached as SCHEDULE 2.5 are true,
correct and complete copies of the Company's unaudited balance sheet as of 30
April 1998 and the related unaudited statement of operations for the four-month
period then ended (the "Interim Financial Statements"). Except as specifically
described in SCHEDULE 2.5, the Financial Statements and the Interim Financial
Statements are complete to the extent required by generally accepted accounting
principles, have been prepared in accordance with generally accepted accounting
principles (except that the Interim Financial Statements do not contain cash
flows, any notes thereto and are subject to normal recurring year-end
adjustments, which if made on the date hereof would not, individually or in the
aggregate, have a material adverse effect on the Company). Subject to the
foregoing sentence, the Financial Statements and the Interim Financial
Statements fairly present in accordance with generally accepted accounting
principles the Company's financial condition of the Company and the results of
its operations and changes in financial position as of the dates and for the
periods reflected therein.
(b) Effective following Closing, the Company will have no
indebtedness for borrowed money. Except as described in SCHEDULE 2.5, the
Company has no liability or obligation related to its assets or business
(whether accrued, absolute, contingent or otherwise), except for (i) the
liabilities and obligations of the Company that are disclosed or reserved
against in the Interim Financial Statements, to the extent and in the amounts so
disclosed or reserved against, (ii) liabilities that were incurred or accrued in
the ordinary course of the Company's business since the date of the Interim
Financial Statements, (iii) the liabilities and obligations of the Company under
the Material Agreements (as that term is defined in Section 2.11), and (iv)
those nonmaterial liabilities and obligations of the Company under contracts and
agreements of the Company that are not Material Agreements.
2.6 AGREEMENT DOES NOT VIOLATE OTHER INSTRUMENTS. Except as set
forth on SCHEDULE 2.6, the execution and delivery of the Transaction Documents
by the Company does not, and the consummation of the transactions contemplated
hereby will not, (a) violate or conflict with any provision of the Articles of
Incorporation, as amended, or Bylaws, as amended, of the Company; (b) require
any consent or approval not previously obtained under, conflict with, result in
the breach, termination or acceleration of, or violate or constitute an
occurrence of default under any provision of any mortgage, deed of trust,
conveyance to secure debt, note, loan, lien, lease, agreement or instrument to
which the Company is a party or by which any of the Company's properties are
bound; (c) constitute a violation of any law, regulation, order, writ, judgment,
injunction, or decree applicable to the Company or by which any of the Company's
properties are bound; (d) result in the creation of any lien upon any of the
assets or business of
-8-
<PAGE> 9
the Company; or (e) have any impact on Medirisk's right after the Closing to
conduct the business of the Company as being conducted by the Company prior to
the Closing.
2.7 LITIGATION. Except as set forth on SCHEDULE 2.7, there is no suit,
action, proceeding, claim or investigation pending or, to the knowledge of the
Company, threatened against, or affecting, the Company; and to the knowledge of
the Company, there exists no basis or grounds for any such suit, action,
proceedings, claim or investigation. SCHEDULE 2.7 also contains a brief
description of any suit, action, proceeding, claim or investigation involving
the Company settled or otherwise concluded since 1 January 1993.
2.8 PERMITS. Except as set forth on SCHEDULE 2.8, the Company holds,
and lists, all licenses, permits and other authorizations from all appropriate
federal, state or other public authorities necessary for the conduct of the
Company's business and the use of its assets, all of which are listed on
SCHEDULE 2.8. The Company is conducting and has conducted its business so as to
comply with all applicable statutes, rules, ordinances, regulations, orders,
injunctions, decrees or any other requirement of any governmental body, agency
or authority binding on it, or relating to its property or business or its
advertising, sales or pricing practices ("Applicable Law") except where the
failure to comply with such Applicable Law would not have a material adverse
affect on the Company, its properties, operations or financial condition.
2.9 TITLE TO ASSETS. Attached as SCHEDULE 2.9 is a list and summary
description of all real property owned or leased by the Company and of all items
of personal property with a fair market value in excess of $5,000.00 owned or
leased by the Company (such list identifying the properties owned by the Company
and all of the leases or agreements under which the Company is lessee of or
holds or operates any property). Except as set forth on SCHEDULE 2.9, the
Company has good and valid title to all of its property and assets, other than
leased property, free and clear of any liens, claims, charges, options, rights
of tenants or other encumbrances, except as disclosed or reserved in the
Financial Statements or the Interim Financial Statements and except for liens
for current taxes not yet due and payable.
2.10 COMPUTER SOFTWARE, INTELLECTUAL PROPERTY.
(a) Attached SCHEDULE 2.10(A) sets forth a complete and correct list
and summary description of all trademarks, trade names, service marks, service
names, brand names, copyrights and patents, registrations thereof and
applications therefor, applicable to or used by the Company in the conduct of
its business, together with a complete list of all licenses granted by or to the
Company with respect to any of the above. All such trademarks, trade names,
service marks, service names, brand names, copyrights and patents reflected on
SCHEDULE 2.10(A) as owned by the Company are owned by the Company free and clear
of all liens, claims, security interests and encumbrances of any nature
whatsoever. All such trademarks, trade names, service marks, service names,
brand names, copyrights and patents reflected on SCHEDULE 2.10(A) as licensed,
leased or otherwise used (but not owned) by the Company are used by the Company
pursuant to terms of binding agreements under which the Company has the right to
use such trademarks, trade names, service marks, service names, brand names,
copyrights and patents as currently used in the Company's business without
payment of any royalty or other fee, except as
-9-
<PAGE> 10
set forth on SCHEDULE 2.10(A). The Company is not currently in receipt of any
notice of violation of, and the Company is not violating the rights of others in
any trademark, trade name, service mark, copyright, patent, trade secret,
know-how or other intangible asset.
(b) Attached SCHEDULE 2.10(B) contains a complete and accurate
list of the computer software, databases and other intellectual property that is
owned by the Company (the "Owned Software"). Except as set forth on SCHEDULE
2.10(B), the Company has exclusive rights and title to the Owned Software, free
and clear of all liens, claims, security interests and encumbrances of any
nature whatsoever, including claims or rights of employees, agents, consultants,
customers, licensees or other parties involved in the development, creation,
marketing, maintenance, enhancement or licensing of such Owned Software. Except
as set forth on SCHEDULE 2.10(B), the Owned Software is not dependent on any
Licensed Software (as defined below) in order to operate fully in the manner in
which it is intended, except for operating systems and third party applications
that are stated in the Owned Software documentation and are readily commercially
available. No Owned Software has been published or disclosed to any other
parties, except as set forth on SCHEDULE 2.10(B) and except pursuant to
contracts requiring such other parties to keep such Owned Software confidential.
To the knowledge of the Company, no such other party has breached any such
obligation of confidentiality.
(c) Attached SCHEDULE 2.10(C) contains a complete and accurate
list of all computer software, databases and other intellectual property that is
used by the Company and for which the Company is the licensee or lessee or
otherwise has legal rights of use (other than commercially available
over-the-counter "shrinkwrap" software) (the "Licensed Software"). SCHEDULE
2.10(C) also sets forth a list of all license fees, rents, royalties or other
charges that the Company is required or obligated to pay with respect to
Licensed Software. Prior to the date of this Agreement, the Company has
delivered to Medirisk true and complete copies of all agreements under which the
Company has the right to use Licensed Software. Except as described on SCHEDULE
2.10(C), the Company has the right and license to use, sublicense, modify and
copy the Licensed Software, free and clear of any limitations or encumbrances
other than the payment of license or royalty fees set forth on SCHEDULE 2.10(C).
The Company is in full compliance with all provisions of any license, lease or
other similar agreement pursuant to which the Company has rights to use the
Licensed Software. Except as disclosed on SCHEDULE 2.10(C), none of the Licensed
Software has been incorporated into or made a part of any Owned Software or any
other Licensed Software. The Company has not published or disclosed any Licensed
Software to any other party except, in the case of Licensed Software that the
Company leases or markets to others, in accordance with and as permitted by any
license, lease or similar agreement relating to the Licensed Software and except
pursuant to contracts requiring such other parties to keep the Licensed Software
confidential. To the knowledge of the Company, no party to whom the Company has
disclosed Licensed Software has breached such obligation of confidentiality.
(d) The Owned Software and the Licensed Software constitute
all software used in relation to the business of the Company (the "Company
Software"). Attached SCHEDULE 2.10(D) sets forth a list of all contract
programmers, independent contractors, nonemployee agents and persons or other
entities (other than employees) who have performed computer
-10-
<PAGE> 11
programming services for the Company in connection with any of the Owned
Software and identifies all contracts and agreements to which the Company is a
party pursuant to which such services were performed. The transactions
contemplated by this Agreement will not cause a breach or default under any
license or similar agreement relating to the Company Software or impair
Medirisk's ability to use the Company Software in the same manner as such
Company Software is currently used by the Company. The Company is not infringing
any intellectual property rights of any other person or entity with respect to
the Company Software, and, to the knowledge of the Company, no other person or
entity is infringing any intellectual property rights of the Company with
respect to the Company Software.
(e) The Company and, to the knowledge of the Company, all
other parties to any licensing or similar arrangements under which the Company
is the licensor or has otherwise granted the right to use the Company Software
are in full compliance with such licensing or similar arrangements and are not
in breach of their obligations with respect thereto. The Company is not a party
to any license, installation agreement, maintenance agreement, data processing
agreement, services agreement or other agreement pursuant to which it is
committed to perform software installation, modifications, enhancements or
services without payment or for payments which, in the aggregate, are less than
the reasonably anticipated cost to perform such installation, modifications,
enhancements or services. The Company has complied in all material respects with
its obligations to its customers and licensees in respect of the Company
Software.
(f) Except as set forth on SCHEDULE 2.10(F), the Company has
granted no marketing rights in the Company Software to any third party, and all
marketing rights granted by any third party to the Company have been granted
exclusively to the Company. SCHEDULE 2.10(F) lists and separately identifies all
agreements pursuant to which the Company has granted or been granted rights to
market software, databases and other intellectual property owned by third
parties.
2.11 CONTRACTS.
(a) Attached as SCHEDULE 2.11(A) is a true and correct list of
all contracts, agreements and other instruments to which the Company is a party
under which the aggregate liability of, or benefit to, the Company could
reasonably be expected to exceed $5,000.00, including without limitation
contracts, agreements and other instruments concerning the following matters
(collectively the "Material Agreements"):
(i) the lease (as lessee or lessor) or license (as
licensee or licensor) of any real or personal property (tangible or intangible);
(ii) the employment, termination, severance or engagement
of or with respect to any officer, director, employee, consultant or agent;
(iii) any arrangement between or among the Company, its
affiliates, the Shareholders, any director, officer or employee thereof and/or
related persons, including without limitation loans, guarantees and credit
arrangements;
-11-
<PAGE> 12
(iv) any arrangement limiting the freedom of the Company
to compete in any manner in any line of business or requiring the Company to
share profits;
(v) any arrangement that could reasonably be
anticipated to have a material adverse effect on the Company, financial or
otherwise;
(vi) any arrangement not in the ordinary course of
business;
(vii) any power of attorney, whether limited or general,
granted by or to the Company;
(viii) any other arrangement that requires performance for
a period of more than ten (10) days or that requires payments in excess of
$5,000.00;
(ix) any loan agreement, contract or other arrangement
relating to the borrowing of money by the Company and the amount outstanding
thereunder or the guarantee by the Company of any third party obligation;
(x) any agreement or arrangement involving intellectual
property rights (other than contracts entered into in the ordinary course of
business with customers and "shrink-wrap" software licenses);
(xi) any contract or arrangement relating to the
provision of data processing, network communication or other technical services
to or by the Company or any affiliate thereof; and
(xii) any contract or arrangement relating to the
provision, purchase or sale of goods or services, other than contracts entered
into in the ordinary course of business and involving payments not in excess of
$5,000.00.
(b) Except as set forth on SCHEDULE 2.11(B), (a) the Material
Agreements are valid and effective in accordance with their terms, and (b) there
is not under any Material Agreement (i) any existing or claimed default by the
Company or (ii) to the knowledge of the Company, any existing or claimed default
by any other party. There is no actual or, to the knowledge of the Company,
threatened termination, cancellation or limitation of any Material Agreements.
To the knowledge of the Company, there is no pending or threatened bankruptcy,
insolvency or similar proceeding with respect to any other party to any of the
Material Agreements.
2.12 TAXES.
(a) The Company has timely and accurately filed all federal,
state, foreign and local tax and information returns and reports required to be
filed by it and has timely paid, or will prior to Closing timely pay, all taxes,
including, without limitation, any and all income, sales, use, withholding,
excise and other taxes (collectively "Taxes") due and owing for all periods
prior to Closing. No liens have been filed and no claims are being asserted or,
to the Knowledge of each of the Shareholders and the Company, contemplated with
respect to any Taxes. No restrictions on assessment or collection of Taxes have
been waived with respect to the Company, and the Company has not consented to
the extension of any statute of limitations with respect to the
-12-
<PAGE> 13
Company relating to Taxes, except for waivers or consents that are no longer in
effect. The Company has received no notice of assessment or proposed assessment
of any Taxes claimed to be owed by it or any other person or entity on its
behalf. No returns, reports or forms filed by or on behalf of the Company with
respect to Taxes are currently being audited or examined, and the Company has
not received any notice of any such audit or examination.
(b) The Company has withheld or collected from each payment made to
each of its employees the amount of all Taxes required to be withheld or
collected therefrom, and the Company has, to the extent due, paid the same to
the proper tax depositories or collecting authorities.
(c) All ad valorem property taxes for years prior to 1998 imposed on
the Company with respect to, or which may become a lien on, its assets have been
paid in full.
2.13 EMPLOYEE BENEFIT PLANS. Attached as SCHEDULE 2.13 is a list of
every pension, retirement, profit-sharing, deferred compensation, severance pay,
vacation, bonus or other incentive plan, any other written or unwritten employee
program, arrangement that involves the expenditure of more than $1,000.00 per
year, agreement or understanding that involves the expenditure of more than
$1,000.00 per year, any medical, vision, dental or other health plan, any life
insurance plan or any other employee benefit plan or fringe benefit plan,
including without limitation any "employee benefit plan," as that term is
defined in Section 3(3) of the Employee Retirement Security Act of 1974, as
amended ("ERISA"), currently or previously adopted, maintained, sponsored or
contributed to by the Company for the benefit of employees, retirees,
dependents, spouses, directors or other beneficiaries and under which employees,
retirees, dependents, spouses, directors or other beneficiaries are eligible to
participate (collectively, the "Benefit Plans"). All of the Benefit Plans (and
any related trusts subject to ERISA) comply with and have been administered in
compliance with the provisions of ERISA, all provisions of the Code, all
applicable state or federal securities laws and all other applicable laws, rules
and regulations. No event has occurred that will or could reasonably be expected
to give rise to a disqualification of any such plan under Sections 401(a) or
501(a) of the Code or to a tax under Section 511 of the Code. Neither the
Company nor any administrator or fiduciary of any such Benefit Plan (or agent or
delegate of any of the foregoing) has engaged in any transaction or acted or
failed to act in any manner that could reasonably be expected to subject the
Company to any direct or indirect liability for a breach of any fiduciary or
co-fiduciary duty under ERISA. No "party in interest" (as defined in Section
3(14) of ERISA) or "disqualified person" (as defined in Section 4975(e)(2) of
the Code) of any Benefit Plan has engaged in any "prohibited transaction"
(within the meaning of Section 4975(c) of the Code or Section 406 of ERISA and
not exempt under Section 408 of ERISA).
2.14 CUSTOMERS. Attached as SCHEDULE 2.14 is a true and correct list of
all of the customers doing in excess of $5,000.00 of business with the Company
during 1995, 1996 and 1997 and to date in 1998 setting forth as to each such
customer its name, address, telephone number and principal person of contact.
The Company has not received any notice, nor does it have any reason to believe,
that any such customer has taken or contemplates taking steps that could disrupt
the business relationship of the Company with such customer.
-13-
<PAGE> 14
2.15 OFFICERS, DIRECTORS AND BANK ACCOUNTS. SCHEDULE 2.15(A) lists the
names of all directors and officers of the Company. SCHEDULE 2.15(B) lists the
name and location of each bank or other institution in which the Company has any
deposit account or safe deposit box, all account numbers and names of all
persons authorized to draw thereon or to have access thereto.
2.16 INTERESTED TRANSACTIONS. Except as set forth on SCHEDULE 2.16, the
Company is not a party to any contract, agreement or other instrument or
transaction with any of the following persons, or in which any of the following
persons have any direct or indirect interest (other than as a shareholder or
employee of the Company);
(a) Any director or officer of the Company or any of the
Shareholders;
(b) Any of the spouses, parents, siblings, children, aunts,
uncles, nieces, nephews, in-laws or grandparents of any of the persons described
in clause (a); or
(c) Any corporation, trust, partnership or other entity in which
any of the persons described in clauses (a) or (b) has a beneficial interest
(other than in a corporation whose shares are publicly traded and in which such
persons own beneficially in the aggregate no more than two percent of the equity
interest).
2.17 ABSENCE OF CERTAIN CHANGES. Since 31 December 1997, and except as
set forth on SCHEDULE 2.17: (a) the Company has operated its business in the
ordinary course; (b) there has not been any change in the business, financial
condition or results of operations of the Company that has had or is reasonably
likely to have a material adverse effect on the Company or its assets or
business; (c) there has not been any damage, destruction or loss (whether or not
covered by insurance) to the Company's assets that has had or is reasonably
likely to have a material adverse effect on the Company or its assets or
business; (d) except as disclosed in SCHEDULE 2.17(D), no customer has canceled,
discontinued or given written or oral notice of its intention to cancel,
discontinue or substantially reduce its business with the Company; and (e)
except as disclosed in SCHEDULE 2.17(E), the Company is not in default and, to
the knowledge of the Company, no customer is in default, under the Company's
contracts with any customer, and each such contract is in full force and effect
on the date of this Agreement, and such customer contracts contain no material
changes from the standard form of agreement used by the Company (including,
without limitation, any deviation from the standard warranties or limitation of
the Company's liability).
2.18 BOOKS AND RECORDS. All books, records and other information
(financial and otherwise), if any, provided by the Company or any Shareholder to
Medirisk are true and correct and accurately reflect the existence of the
Company's assets and the results of operations of the Company's business for the
periods of time stated therein, and such books, records and financial
information reflect revenues and income from the Company's business and not from
other sources, except as expressly disclosed to Medirisk.
-14-
<PAGE> 15
2.19 ACCOUNTS RECEIVABLE AND PAYABLE. The accounts receivable
outstanding as of the date of the Interim Financial Statements are, and the
accounts receivable of the Company outstanding as of the Closing Date will be,
(i) valid and genuine accounts receivable arising only out of bona fide sales
and delivery of goods, performance of services and other business transactions
in the ordinary course of the Company's business consistent with past practice;
(ii) subject to no asserted defenses, counterclaims or rights of setoff, and
(iii) except as set forth on SCHEDULE 2.19, collectible within sixty (60) days
after billing at the full recorded amount thereof less the recorded allowance
for doubtful accounts reflected on the Interim Financial Statements. Except as
set forth on SCHEDULE 2.19, no accounts payable of the Company are, as of the
date of this Agreement, over thirty (30) days old.
2.20 EMPLOYMENT AND LABOR MATTERS.
(a) SCHEDULE 2.20(A) sets forth (i) the number of all
full-time and part-time employees of the Company; (ii) the number of independent
contractors utilized by the Company and (iii) the name and compensation paid to
each independent contractor, employee of or consultant to the Company who
received salary, bonuses or other compensation for either of the Company's two
most recently ended fiscal years in excess of $25,000.00.
(b) To the knowledge of the Company, the Company is in
compliance in all material respects with all applicable laws respecting
employment and employment practices, terms and conditions of employment, wages
and hours, occupational safety and health, including laws concerning unfair
labor practices within the meaning of Section 8 of the National Labor Relations
Act, and the employment of non-residents under the Immigration Reform and
Control Act of 1986.
(c) Except as disclosed on SCHEDULE 2.20(C):
(i) There are no charges, governmental audits,
investigations, administrative proceedings or complaints concerning the
Company's employment practices pending or, to the knowledge of the Company,
threatened before any federal, state or local agency or court, and, to the
knowledge of the Company, no basis for any such matter exists;
(ii) The Company is not a party to any union or
collective bargaining agreement, and, to the knowledge of the Company, no union
attempts to organize the employees of the Company have been made, and no such
attempts are now threatened; and
(iii) The Company has not experienced any organized
slowdown, work interruption, strike, or work stoppage by its employees.
2.21 INSURANCE. Except as described on SCHEDULE 2.21, all of the
assets and business of the Company are insured in such amounts and against such
losses, casualties or risks as are
-15-
<PAGE> 16
customary for similar properties and businesses, and SCHEDULE 2.21 contains a
list of all policies of insurance currently in force with respect to the Company
and its assets and business.
2.22 ENVIRONMENTAL MATTERS. To the knowledge of the Company and except
as set forth in SCHEDULE 2.22, there is no present or past Environmental
Condition in any way relating to the business, properties or assets of the
Company. "Environmental Condition" means (a) the introduction into the
environment of any pollution, including without limitation any contaminant,
irritant or pollutant or other toxic or hazardous substance, in violation of any
federal, state or local law, ordinance or governmental rule or regulations, as a
result of any spill, discharge, leak, emission, escape, injection, dumping or
release of any kind whatsoever of any substance or exposure of any type in any
workplaces or to any medium, including without limitation air, land, surface
waters or ground waters, or from any generation, transportation, treatment,
discharge, storage or disposal of waste materials, raw materials, hazardous
materials, biomedical waste including blood, toxic materials or products of any
kind or from the storage, use or handling of any hazardous or toxic materials or
other substances, as a result of which the Company has or may become liable to
any person or by any reason of which any of the Assets of the Company may suffer
or be subjected to any lien, encumbrance or restriction of any nature, or (b)
any noncompliance with any federal, state or local environmental law, rule,
regulation or order as a result of or in connection with any of the foregoing.
2.23 COMPANY PRODUCTS AND SERVICES. The Company's products and services
conform in all material respects with any specification, documentation,
performance standard, representation or statement made or provided with respect
thereto by or on behalf of the Company, and there has not been during the last
three (3) years any claim made against the Company by any customer of the
Company or by any other person alleging that any product or service of the
Company (including each version thereof that has been licensed or otherwise made
available by the Company to any person) does not conform in all material
respects with any specification, documentation, performance standard,
representation or statement made or provided by or on behalf of the Company,
and, to the knowledge of each of the Company and the Shareholders, there is not
a reasonable basis for any such claim. No material product liability or warranty
claims have been communicated in writing to or threatened in writing against the
Company. To the knowledge of the Company, the Company's products and services,
as of the date hereof, during and after the calendar year 2000 A.D., include
design, function and performance capabilities such that the Company's products
and services shall not abnormally end and/or have invalid and/or incorrect
results from and/or performance or functional degradation because of the
then-current date. To the knowledge of the Company, the design and function of
the Company's products and services ensure year 2000 A.D. functionality and
include, but are not limited to, date data century recognition, calculations
that accommodate same century and multi-century formulas and date values, and
date data interface values that reflect the century. The Company makes no
representations or warranties with respect to whether or not the products or
services of any supplier (including licensors of software) to the Company are
Year 2000 compliant or that the performance of such products, or the provision
of such services, will not be interrupted by Year 2000 issues.
-16-
<PAGE> 17
2.24 SCHEDULES. All Schedules attached hereto are true, correct and
complete as of the date of this Agreement. Matters disclosed on each Schedule
shall be deemed disclosed only for purposes of the matters to be disclosed in
such Schedule and shall not be deemed to be disclosed for any other purpose
unless specifically provided therein.
ARTICLE IIA
2.1A CAPACITY AND AUTHORITY. Each Shareholder represents, severally and
not jointly and severally, that such Shareholder has the capacity and authority
to execute and deliver this Agreement, to perform its obligations hereunder and
to consummate the transactions contemplated by this Agreement without the
necessity of any act or consent of any other person not previously obtained.
This Agreement and each and every agreement, document and instrument to be
executed, delivered and performed in connection with this Agreement by such
Shareholder constitutes or will, when executed and delivered, constitute the
valid and legally binding obligations of such Shareholder, enforceable against
such Shareholder in accordance with their respective terms, except as
enforceability may be limited by applicable equitable principles (whether
applied with action at law or in equity) or by bankruptcy, insolvency,
reorganization, moratorium or similar laws from time to time in effect affecting
the enforcement of creditors' rights generally.
2.2A CAPITALIZATION; OWNERSHIP OF COMPANY STOCK. Each Shareholder
represents, by execution and delivery of this Agreement and/or execution and
delivery of a letter of transmittal or similar instrument referred to in Section
7.2 (a) hereof, that such Shareholder is the legal and beneficial owner of the
number of shares of Company Stock reflected opposite his, her or its name on
SCHEDULE 2.2A, free and clear of all liens, claims, charges, encumbrances,
security interests, pledges or other claims.
ARTICLE III
REPRESENTATIONS AND WARRANTIES OF MEDIRISK AND MERGER SUB
Medirisk and Merger Sub, jointly and severally, represent and warrant
to the Shareholders as follows:
3.1 ORGANIZATION AND STANDING. Medirisk and Merger Sub are each
corporations duly organized, validly existing and in good standing under the
laws of the State of Delaware with the full power and authority to carry on
their respective businesses in the places and as they are now being conducted.
3.2 AUTHORITY AND STATUS. Each of Medirisk and Merger Sub has the
capacity and authority to execute and deliver this Agreement, to perform under
it and to consummate the transactions contemplated by this Agreement without the
necessity of any act or consent of any other person whomsoever. This Agreement
and each and every agreement, document and
-17-
<PAGE> 18
instrument to be executed, delivered and performed by Medirisk or Merger Sub in
connection with this Agreement constitute or will, when executed and delivered,
constitute the valid and legally binding obligations of Medirisk or Merger Sub,
enforceable against Medirisk or Merger Sub in accordance with their respective
terms, except as enforceability may be limited by applicable equitable
principles (whether applied with action at law or in equity) or by bankruptcy,
insolvency, reorganization, moratorium or similar laws from time to time in
effect affecting the enforcement of creditors' rights generally.
3.3 AGREEMENT DOES NOT VIOLATE OTHER INSTRUMENTS. Except as set forth
on SCHEDULE 3.3, the execution and delivery of the Transaction Documents by
Medirisk and Merger Sub do not, and the consummation of the transactions
contemplated hereby will not, (a) violate or conflict with any provision of the
Certificate of Incorporation, as amended, or Bylaws, as amended, of Medirisk or
Merger Sub; (b) require any consent or approval under, conflict with, result in
the breach, termination or acceleration of, or violate or constitute an
occurrence of default under any provision of any mortgage, deed of trust,
conveyance to secure debt, note, loan, lien, lease, agreement or instrument to
which Medirisk or Merger Sub is a party or by which the Company, any Shareholder
or any of their respective properties are bound; or (c) constitute a violation
of any law, regulation, order, writ, judgment, injunction, or decree applicable
to Medirisk or Merger Sub or any of Medirisk's or Merger Sub's properties.
3.4 SEC FILINGS. True, correct and complete copies of the following
documents have been made available to the Shareholders: (i) Medirisk's Annual
Report on Form 10-K for the fiscal year ended 31 December 1997, as filed with
the Securities and Exchange Commission (the "SEC"); and (ii) Medirisk's
Quarterly Reports on Form 10-Q for the three-month period ended 31 March 1998,
respectively, as filed with the SEC (collectively the "SEC Reports"). Since 31
March 1998, there has been no material adverse change in the condition
(financial or otherwise), assets, liabilities, business or operations of
Medirisk that is unique to the business of Medirisk and its consolidated
subsidiaries and that is required to be disclosed by applicable law or by the
rules of the Nasdaq National Market. None of the SEC Reports contains a
misstatement of material fact or omits to state a material fact necessary to be
stated therein in order that the statements made therein are not misleading.
ARTICLE IV
COVENANTS AND UNDERTAKINGS
4.1 COVENANT NOT TO COMPETE. At Closing, Shareholder Ronnie R. Smith,
M.D. ("Dr. Smith") will enter into a Covenant Not to Compete with Medirisk and
Merger Sub substantially in the form of attached EXHIBIT 4.1 (the "Covenant Not
to Compete").
4.2 EMPLOYMENT AGREEMENT. At Closing, Dr. Smith shall enter into an
Employment Agreement with Merger Sub in substantially the form attached hereto
as EXHIBIT 4.2 (the "Employment Agreement").
-18-
<PAGE> 19
4.3 INVESTMENT LETTER. At Closing, each Shareholder receiving Medirisk
Common Stock under SECTION 1.5 will execute and deliver to Medirisk an
investment letter with respect to the Medirisk Common Stock to be delivered to
such Shareholder at Closing substantially in the form of attached EXHIBIT 4.3
(the "Investment Letter").
4.4 SHAREHOLDER CONSENT. Each Shareholder shall execute and deliver a
Shareholder Consent and Power of Attorney substantially in the form of attached
EXHIBIT 4.4 (the "Shareholder Consent") appointing Dr. Smith to act as his, her
or its attorney-in-fact for purposes of this Agreement and the obligations and
covenants of such Shareholder hereunder. In such capacity Dr. Smith (and any
successor of Dr. Smith in such capacity as provided in the Shareholder Consent)
is referred to in this Agreement as the "Shareholders' Representative."
4.5 CONSENTS AND APPROVALS. The Company agrees to use its best efforts
to obtain the waiver, consent and approval of all persons whose waiver, consent
or approval is required in order to consummate the transactions contemplated by
this Agreement, or is required by any agreement, lease, instrument, arrangement,
judgment, decree, order or license to which the Company is a party or subject
that would prohibit, or require the waiver, consent or approval of any person to
such transactions, or under which the consummation of such transactions would
constitute (or with notice or lapse of time would constitute) an event of
default.
4.6 CONDUCT OF THE BUSINESS PRIOR TO CLOSING. Except with the written
consent of Medirisk and except as may be required to effect the transactions
contemplated by this Agreement, between the date of this Agreement and the
earlier of (i) the Merger Effective Time and (ii) the termination of this
Agreement, the Company will (a) not make any distributions of its assets to any
persons except as expressly contemplated by the Schedules hereto; (b) conduct
its operations in the ordinary course of business; (c) keep and maintain its
properties and facilities in good condition, repair and working order,
reasonable wear and tear excepted, and fully insured for liability and property
damages; (d) use its reasonable best efforts to preserve intact its business;
(e) use its reasonable best efforts to retain the service of its employees,
agents and consultants involved with or employed by the Company on terms and
conditions not less favorable than those existing prior to the execution of this
Agreement; (f) cooperate with Medirisk's representatives (without disclosure of
this Agreement or the contemplated sale to the Company's customers or suppliers
without the consent of Medirisk) in reviewing facts and establishing and
implementing procedures necessary to effect the Merger as contemplated by this
Agreement; (g) conduct its activities in a manner consistent with this
Agreement; (h) not enter into, assume or make any contract, loan, license,
designation, loan commitment, purchase, sale or disposition of assets of the
Company outside the ordinary course of business; (i) except for mailing invoices
in the ordinary course of business, not contact any customer regarding
collection of any account receivable and not discount any account receivable;
(j) not declare any dividend or comparable distribution of assets; and (k)
promptly advise Medirisk in writing of any material adverse change in the
Company's financial condition or business affairs.
4.7 TERMINATION OF EMPLOYMENT AGREEMENTS. Each of the Shareholders and
the Company severally agree that any employment or management agreement to which
he or she is a party with the Company will be terminated effective at the
Closing without any further
-19-
<PAGE> 20
action by such individual, the Company or Medirisk, and no party to any such
agreement will have any liability or obligation thereunder of any nature or kind
from and after the Closing Date.
4.8 RESIGNATIONS. At the Closing, the Company will deliver to Medirisk
resignations, effective on or before the Closing Date of each officer and each
director resigning from all director and/or officer positions held by such
person with the Company.
[Document Continued On Next Page]
-20-
<PAGE> 21
ARTICLE V
CONDITIONS PRECEDENT TO OBLIGATIONS OF MEDIRISK AND MERGER SUB
The obligations of Medirisk and Merger Sub to consummate the
transactions contemplated by this Agreement shall be subject to the
satisfaction, on or before the Closing Date, of each and every one of the
following conditions:
5.1 REPRESENTATIONS TRUE AND COVENANTS PERFORMED AT CLOSING. The
representations and warranties made by the Company in this Agreement or any
document or instrument delivered to Medirisk or Merger Sub or its
representatives hereunder shall be true and correct on the Closing Date with the
same force and effect as if such representations and warranties had been made on
and as of the Closing Date. The Company shall have duly performed all of the
agreements, covenants, acts and undertakings to be performed by it on or prior
to the Closing Date.
5.2 NO INJUNCTION, ETC. No action, proceeding, investigation,
regulation or legislation shall have been instituted, threatened or proposed
before any court, governmental agency or legislative body to enjoin, restrain,
prohibit, or obtain substantial damages in respect of, or which is related to,
or arises out of, this Agreement or the consummation of the transactions
contemplated hereby, or which is related to or arises out of the business of the
Company, if such action, proceeding, investigation, regulation or legislation,
in the judgment of Medirisk, would make it inadvisable to consummate such
transactions or would have a material adverse effect on the Company or its
assets or business.
5.3 NO MATERIAL ADVERSE CHANGE. There shall not have been any material
adverse change in the business, assets, liabilities or condition, financial or
otherwise, of the Company between the date of the Interim Financial Statements
and the Closing Date.
5.4 CONSENTS. The Shareholders shall have delivered to Medirisk the
written consents of third parties and all governmental consents and approvals,
if any, referred to in Section 4.5 hereof, which consents shall be in form,
scope and substance reasonably satisfactory to Medirisk and its counsel.
5.5 GOOD STANDING CERTIFICATE. Medirisk shall have received a
Certificate of Existence or Good Standing from the State of Georgia, and from
each other state in which the Company is qualified to transact business as a
foreign corporation, with respect to the Company as of the most recent practical
date prior to the Closing Date.
5.6 DUE DILIGENCE. Medirisk shall in all respects be satisfied in its
discretion with the results of its due diligence investigation of the Company
and its assets and business.
5.7 OPINION OF COUNSEL. Medirisk shall have received an opinion of
counsel to the Company substantially in the form of attached EXHIBIT 5.7.
-21-
<PAGE> 22
ARTICLE VI
CONDITIONS PRECEDENT TO THE
OBLIGATIONS OF THE SHAREHOLDERS TO CLOSE
The obligations of the Company to consummate the transactions
contemplated by this Agreement shall be subject to the satisfaction, on or
before the Closing Date, of each and every one of the following conditions:
6.1 REPRESENTATIONS TRUE AND COVENANTS PERFORMED AT CLOSING. The
representations and warranties made by Medirisk and Merger Sub in this Agreement
or any document or instrument delivered to the Shareholders or their
representatives hereunder shall be true and correct on the Closing Date with the
same force and effect as though such representations and warranties had been
made on and as of such date. Medirisk and Merger Sub shall have duly performed
all of the agreements, covenants, acts and undertakings to be performed by it on
or prior to the Closing Date.
6.2 NO INJUNCTION, ETC. No action, proceeding, investigation,
regulation or legislation shall have been instituted, threatened or proposed
before any court, governmental agency or legislative body to enjoin, restrain,
prohibit, or obtain substantial damages in respect of, or which is related to,
or arises out of, this Agreement or the consummation of the transactions
contemplated hereby.
6.3 OPINION OF COUNSEL. The Shareholders shall have received an opinion
of counsel to Medirisk substantially in the form of attached EXHIBIT 6.3.
ARTICLE VII
CLOSING
7.1 TIME AND PLACE OF CLOSING. The closing (the "Closing") of the
transactions contemplated by this Agreement will be held on 28 May 1998 or such
other date as the parties may agree. The Closing shall commence at 10:00 a.m. at
the offices of Medirisk, Inc., Two Piedmont Center, Suite 400, 3565 Piedmont
Road, N.E., Atlanta, Georgia 30305-1502 or at such other time or place upon
which the parties agree. The date on which Closing occurs shall be referred to
as the "Closing Date."
-22-
<PAGE> 23
7.2 TRANSACTIONS AT CLOSING.
(a) The following deliveries shall be made at the Closing:
(i) The Company shall deliver or cause to be delivered
to Medirisk Certificates of Good Standing of the Company, as of the most recent
practicable date, as contemplated by Section 5.5;
(ii) As contemplated by Section 4.1, Medirisk, Merger
Sub and Dr. Smith shall execute and deliver to each other the Covenant Not to
Compete;
(iii) As contemplated by Section 4.2, Merger Sub and Dr.
Smith shall execute and deliver to each other the Employment Agreement;
(iv) As contemplated by Section 4.3, each of the
Shareholders receiving Medirisk Common Stock shall execute and deliver to
Medirisk an Investment Letter;
(v) As contemplated by Section 4.4, each of the
Shareholders shall execute and deliver to Medirisk a Shareholder Consent;
(vi) Each of the Shareholders (who actually have been
issued share certificates in Company Stock) shall deliver to Medirisk
certificates for the Company Stock formerly representing their shares of Company
Stock, duly endorsed for transfer or accompanied by blank stock powers or
equivalent letter of transmittal;
(vii) Counsel for the Company shall have delivered to
Medirisk the form of opinion attached hereto as Exhibit 5.7; and
(viii) Counsel for Medirisk shall have delivered to the
Shareholders' Representative, on behalf of the Shareholders, the form of opinion
attached hereto as Exhibit 6.3.
(b) At Closing (or as soon as practicable thereafter once all
the items referred to in Section 7.2(a) have been delivered) Medirisk shall:
(i) Cause Merger Sub to disburse the Cash Initial
Consideration as set forth in SCHEDULE 1.5(B)(I) (that portion thereof
deliverable to the Shareholders' Representative on behalf of the Shareholders
who have tendered their certificates representing Company Stock to be allocated
among such Shareholders as set forth on SCHEDULE 1.5(B)(I) under the heading
"Allocation of Cash and Medirisk Common Stock Deliverable to Shareholders").
(ii) Medirisk shall cause Merger Sub to deliver Medirisk
Common Stock to the Shareholders' Representative for allocation to the
Shareholders as set forth on SCHEDULE 1.5(B)(I) under the heading "Allocation of
Cash and Medirisk Common Stock Deliverable to Shareholders."
-23-
<PAGE> 24
[Document Continued On Next Page]
-24-
<PAGE> 25
ARTICLE VIII
SURVIVAL OF REPRESENTATIONS AND WARRANTIES AND INDEMNIFICATION
8.1 SURVIVAL OF REPRESENTATIONS AND WARRANTIES OF THE SHAREHOLDERS
AND MEDIRISK AND INDEMNITY.
(a) All representations, warranties, agreements, covenants and
obligations made or undertaken by the Medirisk, Merger Sub, the Company and the
Shareholders in this Agreement or in any document or instrument executed and
delivered pursuant hereto shall survive the Closing hereunder and shall not
merge in the performance of any obligation by any party hereto.
(b) Subject to the provisions of this Schedule 8, and to the
extent that Medirisk has not been made whole through its rights of withholding
and offset under Section 8.4 hereof, Dr. Smith agrees to indemnify and hold
Medirisk and Merger Sub harmless from and against any Medirisk Indemnified Loss
(as hereinafter defined) suffered or incurred by Medirisk or Merger Sub as a
result of any misrepresentation by, or breach of any covenant or warranty of,
the Company contained in this Agreement or any in any certificate or other
instrument furnished or to be furnished by the Company hereunder.
(c) Subject to the provisions of this Schedule 8, Dr. Smith
agrees to indemnify and hold Medirisk and Merger Sub harmless from and against
any Medirisk Indemnified Loss suffered or incurred by Medirisk or Merger Sub as
a result of any breach of any representation, warranty or covenant of the
Shareholders or any of them in Article IIA hereof or in any certificate or other
instrument furnished or to be furnished by the Shareholders hereunder.
(d) Subject to the provisions of this Schedule 8, Medirisk and
Merger Sub, jointly and severally, agree to indemnify and hold each Shareholder
harmless from and against all liability, loss, damage or injury and all
reasonable costs and expenses (including reasonable counsel fees and costs of
any suit related thereto) suffered or incurred by such Shareholder as a result
of any misrepresentation by, or breach of any covenant or warranty of, Medirisk
or Merger Sub contained in this Agreement or any misrepresentation in or
omission from any certificate or instrument furnished or to be furnished by
Medirisk or Merger Sub hereunder (individually, a "Shareholder Indemnified Loss"
and collectively, the "Shareholder Indemnified Losses").
8.2 NOTICE OF ASSERTED LIABILITY. If any person entitled to
indemnification (an "Indemnified Person") hereunder receives a notice from a
third party of any claim or the commencement (or threatened commencement) of any
action, proceeding or investigation or becomes aware of any circumstances which,
with or without the lapse of time, would give rise to a claim or that may result
in a loss subject to indemnification under this Agreement (an "Asserted
Liability"), the Indemnified Person shall give notice thereof (the "Claims
Notice") to the person required to so indemnify against the Asserted Liability
(an "Indemnifying Person"). The Claims Notice shall describe the Asserted
Liability in reasonable detail and shall indicate the amount
-25-
<PAGE> 26
(estimated, if necessary) of the loss that the Indemnified Person reasonably and
in good faith expects that it may suffer.
8.3 OPPORTUNITY TO DEFEND. The Indemnifying Person may elect to
compromise or defend, at their or its own expense and by their or its own
counsel, any Asserted Liability; provided, however, that the Indemnifying Person
may not compromise or settle any Asserted Liability without the consent of the
Indemnified Person unless such compromise or settlement requires no more than a
monetary payment for which the Indemnified Person hereunder is fully indemnified
or involves other matters not binding upon the Indemnified Person and such
compromise or settlement includes an unconditional release of the Indemnified
Person. If the Indemnifying Person elects to compromise or defend an Asserted
Liability, the Indemnifying Person shall within ten (10) days after receipt of
notice thereof (or sooner, if the nature of the Asserted Liability so requires)
notify the Indemnified Person of his or its intent to do so, and the Indemnified
Person shall cooperate, at the expense of the Indemnifying Person with respect
to out-of-pocket expenses of the Indemnified Person in the compromise of or
defense against such Asserted Liability. The assumption of the defense of a
matter by an Indemnifying Person shall be deemed an admission by such
Indemnifying Person of its obligation to indemnify the Indemnified Person
hereunder with respect to such claim. If the Indemnifying Person elects not to
compromise or defend the Asserted Liability, fails to notify the Indemnified
Person of its election as herein provided or contests its obligation to
indemnify, the Indemnified Person may pay, compromise or defend such Asserted.
In any event, the Indemnified Person and the Indemnifying Person may participate
in the defense of such Asserted Liability in respect of any Asserted Liability
for which the Indemnifying Person has an indemnification obligation; provided
that if the Indemnifying Person assumes the defense or compromise of such
Asserted Liability as provided above, then the Indemnified Person shall bear any
expenses incurred in participating in such defense from and after the assumption
of the defense thereof by the Indemnifying Person.
8.4 WITHHOLDING AND OFFSET. Medirisk shall be obligated to (a) first
withhold from the payments due under Section 1.5(b)(ii) the amount of any and
all liabilities, losses, damages, injuries, costs, expenses and counsel fees
that it has sustained or that it reasonably believes may be sustained on account
of any misrepresentation by, or breach of any covenant or warranty of, the
Company or the Shareholders and arising from a specific allegation made by or
against Medirisk or Merger Sub (individually, a "Medirisk Indemnified Loss" and
collectively, the "Medirisk Indemnified Losses") and (b) then offset from such
withheld amount any amount (but only such amounts) ultimately determined to be a
Medirisk Indemnified Loss pursuant to this Schedule 8. Neither Medirisk nor
Merger Sub shall be liable for breach of this Agreement on account of any
amounts so withheld and set off so long as its actions are taken reasonable, in
good faith and otherwise in accordance with requirements of this Agreement. If
the withholding of payments under this Section 8.4 has been based on a
reasonable belief of a future claim due to a specific allegation, Medirisk shall
pay the amount withheld to the Shareholders' Representative within one (1) year
of the original payment date of the amount withheld unless previously offset
pursuant to the preceding sentence or unless a lawsuit, arbitration or
administrative proceeding based on such claim shall have been commenced within
said one-year period. If such a lawsuit, arbitration or administrative
proceeding has commenced within said one-year period, then Medirisk shall pay
within ninety (90) days after a final determination under such lawsuit,
-26-
<PAGE> 27
arbitration or administrative proceeding, the difference if any, between said
withheld amount and the amount of any Medirisk Indemnified Loss if the withheld
amount is larger, plus interest on the amount overwithheld at the 90-day CD rate
of NationsBank, N.A., Atlanta, Georgia, then in effect.
8.5 NO CLAIM AGAINST COMPANY, ETC. Since following the Merger the
Company will cease to exist due to its merger with and into Merger Sub, which
will be wholly-owned by Medirisk, the parties agree that the Shareholders will
have no right of indemnification, reimbursement or contribution against Merger
Sub (in its capacity as successor-in-interest by merger to the Company or
otherwise) or any other party hereto on account of any Medirisk Indemnified Loss
hereunder. In addition, any liability, loss, damage or injury suffered or
incurred by Merger Sub against which Merger Sub and/or Medirisk is indemnified
and held harmless as provided in Section 8.1 of this Agreement shall be deemed
suffered by Medirisk, which shall, either independently or jointly with the
Merger Sub, be entitled to enforce such indemnity.
8.6 LIMITATIONS.
(a) Notwithstanding the provisions of Section 8.1(b) above,
there shall be no right of withholding or offset, and Dr. Smith shall not be
required to make any indemnification payments under Section 8.1(b) until the
aggregate amount of losses suffered by Medirisk and Merger Sub that are subject
to indemnification under such Section exceed Fifty Thousand and No/100
($50,000.00.00) Dollars (the "Minimum Indemnity Amount"), at which time claims
may be asserted for all amounts up to and in excess of the Minimum Indemnity
Amount.
(b) Notwithstanding the provisions of Section 8.1(b) or 8.1(c)
above, the maximum liability of Dr. Smith for indemnification under this
Agreement shall be equal to the Merger Consideration.
(c) Notwithstanding the provisions of Section 8.1(d) above,
and except for any Shareholder Indemnified Loss resulting from a breach of the
covenants, representations and warranties set forth in SCHEDULE 1.5(B)(II), the
maximum aggregate liability of Medirisk and Merger Sub for indemnification under
this Agreement shall be equal to the Merger Consideration.
(d) Notwithstanding the provisions of Section 8.1 above, no
claim for indemnification under this Agreement may be made after 31 August 1999,
unless notice of such claim or the facts underlying it is given to the
indemnifying party prior to 31 August 1999; provided, however, that the
foregoing restriction shall not apply with respect to (i) any Medirisk
Indemnified Loss resulting from a breach of the covenants, representations and
warranties set forth in Sections 2.1, 2.2, 2.3, 2.9, 2.12, 2.13, 2.1A or 2.2A;
and (ii) any liability, loss, damage, injury or claim by the Shareholders
resulting from a breach of the covenants, representations and warranties set
forth in Schedule 1.5(b)(ii) and Sections 3.1 and 3.2; provided further that any
claim based upon any of the matters described in subsection (i) or (ii) may be
brought at any time, subject to any applicable statutes of limitation.
-27-
<PAGE> 28
ARTICLE IX
TERMINATION
9.1 METHOD OF TERMINATION. This Agreement and the transactions
contemplated by it may be terminated at any time prior to the Closing Date:
(a) By the mutual consent of the Shareholders' Representative
and Medirisk;
(b) By the Shareholders' Representative after 31 May 1998 if
Medirisk or Merger Sub shall (i) fail to perform in any material respect its
agreements contained herein required to be performed by it on or prior to the
Closing Date, or (ii) materially breach any of its representations, warranties
or covenants contained herein;
(c) By Medirisk after 31 May 1998, if any Shareholder shall
(i) fail to perform in any material respect his, her or its agreements contained
herein required to be performed by him, her or it on or prior to the Closing
Date, or (ii) materially breach any of his, her or its representations,
warranties or covenants contained herein;
(d) By the Shareholders' Representative or Medirisk at any
time after 30 June 1998 if the Closing shall not have occurred for any reason on
or prior to 30 June 1998.
(e) By either Medirisk or the Shareholders' Representative if
there shall be any order, writ, injunction or decree of any court or
governmental or regulatory agency binding on Medirisk, Merger Sub, the Company
or any Shareholder, which prohibits or restrains Medirisk, Merger Sub, the
Company and/or any Shareholder from consummating the Merger hereunder, provided
that Medirisk and the Shareholders shall have used their reasonable best efforts
to have any such order, writ, injunction or decree lifted and the same shall not
have been lifted within ten (10) days after entry, by any such court or
governmental or regulatory agency.
9.2 NOTICE OF TERMINATION. Notice of termination of this
Agreement, as provided for in this Article IX, shall be given by the parties so
terminating to the other parties hereto in accordance with Section 10.1 of this
Agreement.
9.3 EFFECT OF TERMINATION. If this Agreement is terminated
pursuant to Section 9.1 hereof, this Agreement shall become void and of no
further force and effect, and each party shall pay the costs and expenses
incurred by it in connection with this Agreement; and, provided the Agreement
was not terminated pursuant to subparagraph (b) or (c) of Section 9.1, no party
(or any of its officers, directors, employees, agents, representatives or
shareholders) shall be liable to any other party for any costs, expenses,
damages (direct or indirect) or loss of anticipated profits. If, however, this
Agreement is terminated pursuant to subparagraphs (b) or (c) of Section 9.1,
this Section 9.3 shall not relieve a breaching or defaulting party from any
liability to the other party.
-28-
<PAGE> 29
9.4 RISK OF LOSS. The Company and the Shareholders shall bear all risk
of condemnation, destruction, loss or damage due to fire or other casualty from
the date of this Agreement through the Closing. If the condemnation,
destruction, loss or damage is such that the business of the Company is
interrupted or curtailed or the assets of the Company are materially affected,
then Medirisk shall have the right to terminate this Agreement. If the
condemnation, destruction, loss or damage is such that the business is neither
interrupted nor curtailed or the assets are not materially affected, or if the
business of the Company is curtailed or interrupted or the assets are materially
affected and Medirisk nevertheless forgoes the right to terminate this
Agreement, then the Merger Consideration shall be adjusted at Closing to reflect
such condemnation, destruction, loss or damage to the extent that insurance
proceeds are not sufficient to cover such destruction, loss or damage. If
Medirisk, on the one hand, and the Shareholders, on the other, are unable to
agree upon the amount of such adjustment, then the dispute shall be resolved
jointly by the independent accounting firms then employed by the Company and
Medirisk, and if said accounting firms do not agree, they shall appoint a
Designated Accountant (in the manner prescribed in SCHEDULE 1.5(B)) to make such
determination, whose determination of the dispute shall be final and binding.
For purposes of this Section 9.4 the fees and expenses of the Designated
Accountant shall be borne one-half by Medirisk and one-half by Shareholders.
ARTICLE X
GENERAL PROVISIONS
10.1 NOTICES. (a) All notices, requests, demands and other
communications hereunder shall be in writing and shall be delivered by hand,
facsimile or mailed by nationally recognized overnight delivery service or by
registered or certified mail, return receipt requested, first class postage
prepaid, addressed as follows:
IF TO ANY SHAREHOLDER:
Ronnie R. Smith, Shareholders' Representative
900 East First Street
P.O. Box 1955
Vidalia, Georgia 30475
Facsimile : (912) 537-6387
-29-
<PAGE> 30
With a copy (which shall not constitute
notice) to:
Howard C. Kaufold, Jr., Esq.
Newton, Smith, Durden, Kaufold, Rice & Tribble
3110 First East Street
P.O. Box 1935
Vidalia, Georgia 30475-1935
Facsimile : (912) 537-1821
IF TO MEDIRISK:
Medirisk, Inc.
Two Piedmont Center, Suite 400
3565 Piedmont Road
Atlanta, Georgia 30305-1502
Attention: Legal Department
Facsimile: (404) 364-6703
(b) If delivered personally or by facsimile, the date on which
a notice, request, instruction or document is delivered shall be the date on
which such delivery is made and, if delivered by mail, the date on which such
notice, request, instruction or document is received shall be the date of
delivery.
(c) Any party hereto may change its address specified for
notices herein by designating a new address by notice in accordance with this
Section 10.1.
10.2 BROKERS. Medirisk and Merger Sub represent and warrant to the
Shareholders, and the Shareholders jointly and severally represent and warrant
to Medirisk and Merger Sub, that, except as disclosed in SCHEDULE 10.2, no
broker or finder has acted for it or them or any entity controlling, controlled
by or under common control with it or them in connection with this Agreement.
10.3 FURTHER ASSURANCES. Each party covenants that at any time, and
from time to time, after the Closing, it will execute such additional
instruments and take such actions as may be reasonably requested by the other
parties to confirm or perfect or otherwise to carry out the intent and purposes
of this Agreement.
10.4 WAIVER. Any failure on the part of any party hereto to comply
with any of its obligations, agreements or conditions hereunder may be waived by
any other party to whom such compliance is owed. No waiver of any provision of
this Agreement shall be deemed, or shall constitute, a waiver of any other
provision, whether or not similar, nor shall any waiver constitute a continuing
waiver.
-30-
<PAGE> 31
10.5 EXPENSES. All expenses incurred by the parties hereto in
connection with or related to the authorization, preparation and execution of
this Agreement and the Closing of the transactions contemplated hereby,
including, without limitation of the generality of the foregoing, all fees and
expenses of agents, representatives, counsel and accountants employed by any
such party, shall be borne solely and entirely by the party which has incurred
the same. The Shareholders agree that the Company shall not pay any expenses in
connection with or related to the authorization, preparation and execution of
this Agreement or the Closing of the transactions contemplated hereby (all such
expenses to be paid by the Shareholders from the Cash Initial Consideration
according to their proportionate interests in the Company) and that, if the
Company pays any such expenses, Shareholders shall promptly reimburse the
Company for any amount so paid.
10.6 BINDING EFFECT. This Agreement shall be binding upon and inure to
the benefit of the parties hereto and their respective heirs, legal
representatives, executors, administrators, successors and assigns.
10.7 HEADINGS. The section and other headings in this Agreement are
inserted solely as a matter of convenience and for reference, and are not a part
of this Agreement.
10.8 ENTIRE AGREEMENT. This Agreement constitutes the entire agreement
among the parties hereto and supersedes and cancels any prior agreements,
representations, warranties, or communications, whether oral or written, among
the parties hereto relating to the transactions contemplated hereby or the
subject matter herein. Neither this Agreement nor any provision hereof may be
changed, waived, discharged or terminated orally, but only by an agreement in
writing signed by the party against whom or which the enforcement of such
change, waiver, discharge or termination is sought.
10.9 GOVERNING LAW. This Agreement shall be governed by and construed
in accordance with the laws of the State of Georgia.
10.10 COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.
[Document Continued On Next Page]
-31-
<PAGE> 32
10.11 PRONOUNS. All pronouns used herein shall be deemed to refer to
the masculine, feminine or neuter gender as the context requires.
IN WITNESS WHEREOF, each party hereto has executed or caused this
Agreement to be executed on its behalf, all on the day and year first above
written.
MERGER SUB:
MEDIRISK, INC. SUCCESSFUL SOLUTIONS, INC.,
a Delaware corporation
By: /s/ Eric W. Ohlhausen By: /s/ Thomas C. Kuhn III
-------------------------- -----------------------
ERIC W. OHLHAUSEN THOMAS C. KUHN III
Vice President Vice President
COMPANY:
SUCCESSFUL SOLUTIONS, INC.,
a Georgia corporation SHAREHOLDERS:
By: /s/ Ronnie R. Smith /s/ Ronnie R. Smith, M.D.
-------------------------- -----------------------
RONNIE R. SMITH RONNIE R. SMITH, M.D., in
Chief Executive Officer his Individual Capacity and
as Attorney-In-Fact for the
following Shareholders:
HARVEY V. APPLE
JOAN CULLEY
PAMELA S. HAMILTON
HOWARD HOLMAN
ROBERT LITTLE
JIMMY M. MEADOWS
JAMES S. WELCH
<PAGE> 1
EXHIBIT 99.1
[MEDIRISK (SM) LETTERHEAD]
Contact: Mark A. Kaiser
Chairman and CEO
(404) 364-6700
MEDIRISK ACQUIRES SUCCESSFUL SOLUTIONS, INC.
ATLANTA, Georgia (May 28, 1998) Medirisk, Inc. (Nasdaq/NM:MDMD), a leading
provider of proprietary database products, decision-support software and
analytical services to the health care industry, today announced the acquisition
of Successful Solutions, Inc., a health care information company that offers
analytical tools and services for profiling the performance of physicians,
implementing improved treatment protocols and ensuring proper coding for
clinical and billing records.
Medirisk purchased Successful Solutions, Inc. for approximately $2.9
million in cash and 190,000 shares of Medirisk common stock. Contingent
consideration in stock and cash is payable if Successful Solutions achieves
certain financial objectives. Medirisk expects to record a non-recurring charge
of approximately $4.0 million in the second quarter of 1998 relating to the
acquisition of in-process research and development and approximately $400,000
during 1998 for planned integration costs. Medirisk will account for the
acquisition of Successful Solutions as a purchase transaction. This transaction
marks Medirisk's eighth acquisition since January 1996, and the sixth
acquisition since its 1997 initial public offering.
Successful Solutions provides decision-support tools, consulting services,
and training materials to hospitals and physician group practices to assist them
in improving patient outcomes, achieving the efficient delivery of care and
establishing billing and coding practices that comply with industry
requirements. Successful Solutions collects clinical and billing record data
from its customers and profiles the relative performance of individual
physicians using its analytical tools and statistical algorithms. Successful
Solutions implements on-site education through physician consultants and medical
record specialists to influence physician behavior and promote the effective and
efficient delivery of health care. Successful Solutions' tools and services for
bill coding and medical record documentation help its customers achieve optimal
and appropriate reimbursement for services delivered, while improving the
quality of data for future comparative analysis.
-MORE-
<PAGE> 2
Medirisk Acquires Successful Solutions, Inc.
Page 2
May 28, 1998
Mark A. Kaiser, Medirisk's chairman and chief executive officer, stated,
"Our acquisition strategy continues to focus on increasing market share within
existing product lines and expanding into complementary product areas.
Successful Solutions expands our Clinical Performance product line to include
information products and analytical tools that profile physician performance.
These new products complement our existing databases and products that measure
service utilization, clinical outcomes and physician credentials. The
acquisition of Successful Solutions advances our product strategy in the area of
physician profiling."
Medirisk, Inc. is a leading provider of proprietary database products,
decision-support software and analytical services to the health care industry.
The Company's products and services enable its customers to make objective
comparisons of the financial costs and clinical outcomes of physician services
to customer-specific and industry benchmarks, analyze the supply of and demand
for health care services, assess patient satisfaction with specific managed care
plans and obtain information concerning the background and credentials of
physicians. These capabilities assist health care industry participants in
measuring the performance of health care payers and providers. Medirisk's
corporate headquarters are located in Atlanta, Georgia.
This press release, particularly the statements by Mr. Kaiser, includes
forward-looking statements related to Medirisk that involve risks and
uncertainties including, but not limited to, quarterly fluctuations in results,
the management of growth, market acceptance of certain products and other risks.
These forward-looking statements are made in reliance on the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995. For further
information about these factors that could affect Medirisk's future results,
please see the Company's recently filed Form S-3, as amended (Registration
Number 333-50015) and its other filings with the Securities and Exchange
Commission. Prospective investors are cautioned that forward-looking statements
are not guarantees of future performance Actual results may differ materially
from management expectations. Copies of the filings are available upon request
from Medirisk's investor relations department.
-END-
